Diabetes Mellitus, Type 2 Diabetes Mellitus
Conditions
Interventions
This was a two-arm, double-blind, randomized controlled clinical trial. A total of 94 individuals who met the eligibility criteria were probabilistically allocated to either intervention group using a
Sponsors
Universidade de Pernambuco
Universidade de Pernambuco
Eligibility
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Having a diagnosis of type 2 diabetes mellitus; aged between 18 and 59 years; both sexes; being on oral hypoglycemic treatment or combination therapy for at least 6 months; not undergoing any antioxidant therapy, such as vitamin supplements; having no known allergy to the components used in the treatments
Exclusion criteria
Exclusion criteria: Patients with type 1 diabetes; pregnant or lactating women; patients with severe heart disease, liver disease, or renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: An improvement in glycemic metabolism is expected, as assessed by fasting blood glucose and glycated hemoglobin (HbA1c) biochemical assays, evidenced by a significant reduction in these parameters in the treatment group compared to the control group post-intervention and/or within the resveratrol-treated group.;Observed outcome 1: A statistically significant reduction (p = 0.020) in glycated hemoglobin (HbA1c) was observed within the resveratrol-treated group from pre- to post-intervention, as assessed by biochemical analysis followed by statistical evaluation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: An improvement in lipid metabolism is expected, as assessed by total cholesterol, LDL, HDL, and triglycerides biochemical assays, evidenced by a significant reduction in these parameters in the treatment group compared to the control group post-intervention and/or within the resveratrol-treated group.;Observed outcome 2: A significant increase (p < 0.001) in triglycerides was observed in the control group compared to the resveratrol-treated group post-intervention. Additionally, a statistically significant reduction (p < 0.001) in LDL and a significant increase (p = 0.005) in HDL were observed within the resveratrol-treated group from pre- to post-intervention, as assessed by biochemical analysis followed by statistical evaluation.;Expected outcome 3: A reduction in the waist-to-hip ratio (WHR) is expected, as assessed by waist and hip circumference measurements, evidenced by a significant reduction in this parameter in the treatment group compared to the control group post-intervention and/or within the resveratrol-treated group.;Observed outcome 3: A statistically significant reduction (p = 0.013) in the waist-to-hip ratio (WHR) was observed in the treatment group compared to the control group post-intervention. Additionally, a statistically significant reduction (p = 0.017) in WHR was observed within the resveratrol-treated group from pre- to post-intervention, as assessed by waist and hip circumference measurements followed by statistical evaluation.;Expected outcome 4: An improvement in sleep quality is expected, as assessed by the Pittsburgh Sleep Quality Index (PSQI) global score and nocturia frequency, evidenced by a significant reduction in the index score and nocturia in the treatment group compared to the control group post-intervention and/or within the resveratrol-treated group.;Observed outcome 4: A statistically significant reduction (p = 0.038) in nocturia frequency was observed in the treatment group compared to the control | — |
Countries
BR
Contacts
Public ContactCarlos Dias
Universidade Federal do Vale do São Francisco
Outcome results
None listed